title: Eosinophil infiltration precedes development of airway hyperreactivity and mucosal exudation after intranasal administration of interleukin-5 to mice.
abstract: Recently, we demonstrated that antibody to interleukin-5 (IL-5) prevents the infiltration of eosinophils in the respiratory airways and the development of bronchial hyperreactivity in an animal model of allergic asthma. In this study we investigated the influence of long-term intranasal administration of IL-5 on airway responsiveness in vitro, the infiltration of inflammatory leukocytes, and mucosal exudation. Mice (BALB/c) received 1 microgram of recombinant human IL-5 in 30 microliters of saline solution or vehicle alone twice a day for 1, 3, and 7 days. At 3 and 7 days after IL-5 administration, the number of bronchoalveolar lavage eosinophils increased approximately fourfold and sixfold, respectively. Blood eosinophil numbers showed a similar increase. In addition, 7 days after IL-5 treatment, total lung eosinophil peroxidase activity was significantly increased by 170% as compared with controls. The maximal responsiveness of the trachea in vitro to methacholine was significantly increased by 34%, as compared with controls, only at 7 days after IL-5 administration. Furthermore, mucosal exudation was also only increased significantly at 7 days after IL-5 administration. It can be concluded that the IL-5-induced eosinophil infiltration precedes the development of airway hyperreactivity and mucosal exudation.
authors.affiliation: Department of Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, The Netherlands.
authors.forename: A J
authors.initials: AJ
authors.lastname: Van Oosterhout
authors.forename: D
authors.initials: D
authors.lastname: Fattah
authors.forename: I
authors.initials: I
authors.lastname: Van Ark
authors.forename: G
authors.initials: G
authors.lastname: Hofman
authors.forename: T L
authors.initials: TL
authors.lastname: Buckley
authors.forename: F P
authors.initials: FP
authors.lastname: Nijkamp
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D001773:Blood Cells / Q000473:pathology; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D002465:Cell Movement; D004804:Eosinophils / Q000502:physiology*; D005122:Exudates and Transudates / Q000378:metabolism*; D015848:Interleukin-5 / Q000008:administration & dosage* / Q000494:pharmacology; D007958:Leukocyte Count; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009092:Mucous Membrane / Q000378:metabolism; D012130:Respiratory Hypersensitivity / Q000473:pathology / Q000503:physiopathology*; D012137:Respiratory System / Q000378:metabolism*; D014132:Trachea / Q000503:physiopathology
chemical_list: D015848:Interleukin-5